Serum alpha-fetoprotein (AFP) monitoring in isolation is this website of limited value in surveillance for the development of HCC and should be used in combination with ultrasound. Six monthly liver ultrasound is preferred as this may detect tumours early enough to enable curative treatment to be undertaken [12]. Testing of partners of HCV RNA positive patients.  There

is a small risk of HCV infected patients transmitting the infection to their partners through sexual intercourse. Cohort studies of couples discordant for HCV indicated an HCV incidence of 0–2 per 1000 years of sexual contact [12]. Partners should be offered HCV testing and those found to be negative and at continuing risk should be intermittently retested. There is no evidence based guideline to inform the frequency of retesting. This should be decided upon on an individual basis following discussion between the couple and their clinician. 1  HCV antibody positive patients should undergo HCV RNA PCR testing and if positive should be referred to a hepatologist for further assessment including RNA quantitation, HCV genotyping and assessment of the stage of liver damage (1C). HCV RNA PCR negative patients do not require further investigation. The Kinase Inhibitor Library pharmacological

treatment of HCV in patients with hereditary bleeding disorders is no different from that of other infected individuals and should follow established guidelines such as those recently published by the American Association for the Study of the Liver [6]. Pegylated interferon (PegIFN) and ribavirin combination therapy is the present standard treatment for HCV. This regimen should be offered to treatment naïve patients with chronic HCV-related liver

disease and patients who have failed to respond to or relapsed following previous interferon monotherapy or standard interferon and ribavirin combination therapy [21–23]. It is recommended that HCV RNA levels are checked at 4 weeks and 12 weeks to assess the initial viral kinetic responses to treatment. A rapid virological response (RVR – defined as clearance of HCV at 4 weeks) is highly predictive of achieving a sustained virological 上海皓元医药股份有限公司 response (SVR – defined as undetectable HCV RNA 24 weeks following discontinuation of therapy) independent of genotype [6]. Early virological response (EVR – defined as at least a two log reduction in viral load) is assessed at 12 weeks. Absence of an EVR is highly predictive of failure to achieve SVR especially in patients with genotype 1 and treatment should be discontinued. Patients not achieving a complete EVR (undetectable HCV at week 12) should be retested at 24 weeks and if HCV RNA is still detectable treatment should be discontinued. Patients with genotypes 2 and 3 who achieve either an RVR or complete EVR should be treated for 24 weeks [6]. Genotype 1 patients who have an RVR can also discontinue therapy at 24 weeks without reducing their chances of achieving an SVR [6].

Hence, it is clinically obvious that the term progression needs to be refined to become a valid surrogate of outcome. This justifies the novel concept of “untreatable progression” (Fig. 1), defined by progression associated

with a profile that prevents retreatment or, by this failing, to induce an objective response. Untreatable progression includes major progression (e.g., massive liver involvement, extrahepatic spread, and vascular invasion), but also minor intrahepatic progression with impaired liver function and performance status that contraindicate treatment. Accordingly, chemoembolization should not be repeated in the following situations: (1) when it fails to achieve significant necrosis after two treatment sessions; (2) when follow-up treatment fails to induce significant tumor necrosis of progressed tumor sites; and (3) when the evaluation of the patient with progression prevents safe retreatment. The first option indicates treatment PD-L1 inhibitor cancer failure, and the second options should be registered as untreatable progression and its

occurrence during follow-up is time to untreatable progression (TTUP). Tumor-burden reduction has been the backbone of the evaluation of systemic agents.21, check details 22 Rate of objective response (including complete and partial) was used to capture promising efficacy signals of novel agents before phase III trials. This approach may have discarded agents that, though not reducing tumor mass, could have had a benefit on survival by delaying tumor progression and death. This possibility has been proven with sorafenib, an oral multikinase inhibitor. In the initial phase II study,36 the rate of objective responses was marginal, but the observed TTP became the background for the design

of the phase medchemexpress III trials that had survival as endpoint.37, 38 Interestingly, treatment was not interrupted at the time of progression. This already took into account that progression may be a heterogeneous event, as already mentioned, and that its detection by follow-up imaging may not always reflect treatment failure. The demonstration that a beneficial effect could be achieved without tumor reduction has primed the research of functional imaging that would capture the effects of drugs in tumor tissue. Antiangiogenics induce changes in tumor vascularization, and this may be identified by parameters such as blood flow, blood volume, permeability perfusion, or K-trans value.39, 40 To date, there are no data to support the use of these techniques to define whether a drug has any efficacy or whether it fails. Assessment of the reduction of tumor density after contrast administration aiming to reproduce the Choi criteria for gastrointestinal stromal tumors41 has not provided useful criteria for HCC. It is important to note that even if antiangiogenics may decrease tumor density upon contrast administration, this should not be taken as tumor necrosis.

While the use of such a proxy for sun time may be justified for short-term studies close to the equator, where the difference is small, the increase of this difference with increasing duration

and latitude has never been quantified. We thus aimed at characterizing the potential error in recording behaviours with a clock, according to study duration and geographical location. The main goal of this work is to provide a simple tool for correcting the time at which behaviours are recorded when using a clock in order to make it corresponds to solar time. To highlight the importance of this, we first used a simple mathematical model to investigate the potential error of recording behaviours based on ‘clock time’, according to both the location and the duration of the study. selleckchem We used the example of a simulated behaviour set at sunrise for ease of demonstration. We then used a real Fludarabine dataset, from a long-term study of the ecology of African wild dogs, Lycaon pictus, in Zimbabwe, to illustrate how using clock time rather than sun time may result in some artificial noise and thus

to different conclusions regarding the observed behaviours. Moreover, we assessed the frequency of using a clock to record behaviours in published studies. We investigated 100 peer-reviewed papers studying various species and behaviours, lasting for different 上海皓元 periods of time and located in a wide range of latitudes. Finally, we discuss the implication of this factor for the future collection of ethological,

behavioural and demographic data as well as for the analysis of existing data. Determining the time of sunset (-rise) according to the date and latitude (Meeus, 1991; Meeus & Savoie, 1995; Savoie, 2001; and see Appendix S1) enables us to model an event occurring at sunrise (and recorded by clock time). Then, we intend to estimate the loss of information expressed as the noise due to change in sunrise while recording data using clock time. We set a hypothetical behaviour occurring at sunrise. The demonstration holds for other moments of the day, such as zenith or sunset. For the sake of realism, the occurrence of this behaviour is not instantaneous, but rather follows a normal distribution centred on sunrise: (1) The density of probability reaches its maximum at HSrise, meaning the best way to observe the behaviour is to watch the individuals at this time of the day. The probability density decreases symmetrically around its maximum, meaning the further one is from HSrise, the less chance one has to observe the behaviour. If a behaviour is to be observed daily over an N-day period, one can assess the overall distribution of the timing of the behaviour using either sun time or clock time.

Results: The incidence cohort consisted of 254 cases with 78% males and a mean age of 65.6 years. Forty-eight percent were Caucasian, with Asians 20%, Mediterraneans 18% and Africans 10%. Cirrhosis was present in 86% of patients. Chronic HCV infection (42%)

was the commonest cause of underlying liver disease, followed by alcohol (39%), chronic HBV infection (18%), and NAFLD (12%). Overall only 14% were diagnosed by biopsy. Diagnosis of HCC outside a screening program occurred in 54%. HCC diagnosed by screening were more likely to have early stage disease (BCLC 0 to B) than those diagnosed outside a screening program (52.5% vs. 9.5%, p < 0.0001). The age-standardized incidence rates (per 100,000 Australian Standard Population) for Melbourne were 8.05 in males and 2.12 in females, compared to Victorian incidence rates in 2011 of 5.2 and 1.2, respectively

(Victorian Cancer Registry 2012). Conclusion: In the first population-based incidence Small molecule library molecular weight study of HCC in Australia, we have shown that the incidence of HCC in Melbourne ICG-001 datasheet is higher than previously reported in Victoria. This has important implications for the allocation of healthcare resources. Hepatitis C and alcohol are the leading causes of HCC. Tumours diagnosed within surveillance programs had earlier stage disease, suggesting that increased uptake of surveillance may improve clinical outcomes. X ZHOU,1 K SHAW,1 L ALGIE,2 J FAWCETT,2 K STUART1 1Department of Gastroenterology and Hepatology Princess Alexandra Hospital, Brisbane, Australia, 2Liver Transplant Services, Princess Alexandra Hospital, Brisbane, Australia

Background: The Barcelona Clinic Liver Cancer (BCLC) staging system is the most widely used treatment algorithm for Hepatocellular Carcinoma (HCC). Patient performance status (PS) is a key component of the revised BCLC criteria. Patients with an ECOG status of ≥1 are categorised as BCLC Stage C irrespective of tumour size and number. Other HCC staging systems place more emphasis on the characteristics of the tumour than the health status of the patient in their treatment decision making process. Aims and methods: The aim of this study was to assess the influence of PS on treatment selection and overall survival in patients with BCLC Early Stage HCC. A retrospective review was conducted of all patients with 上海皓元医药股份有限公司 BCLC Early HCC who were treated with curative intent using radiofrequency ablation (RFA), surgical resection (SR) or liver transplantation (LT) at a single Australian liver transplant centre between January 2005 and June 2012. Early HCC was defined as a single tumour ≤6.5 cm or ≤3 tumours, none greater than 4.5 cm in maximum diameter with a total tumour diameter of ≤8 cm. Patients were divided into two groups based on their PS (ECOG 0–1; good performance group, ECOG ≥2 poor performance group). Demographic data, clinical and laboratory characteristics, treatment selection and overall survival were compared between the two groups.

Results: The incidence cohort consisted of 254 cases with 78% males and a mean age of 65.6 years. Forty-eight percent were Caucasian, with Asians 20%, Mediterraneans 18% and Africans 10%. Cirrhosis was present in 86% of patients. Chronic HCV infection (42%)

was the commonest cause of underlying liver disease, followed by alcohol (39%), chronic HBV infection (18%), and NAFLD (12%). Overall only 14% were diagnosed by biopsy. Diagnosis of HCC outside a screening program occurred in 54%. HCC diagnosed by screening were more likely to have early stage disease (BCLC 0 to B) than those diagnosed outside a screening program (52.5% vs. 9.5%, p < 0.0001). The age-standardized incidence rates (per 100,000 Australian Standard Population) for Melbourne were 8.05 in males and 2.12 in females, compared to Victorian incidence rates in 2011 of 5.2 and 1.2, respectively

(Victorian Cancer Registry 2012). Conclusion: In the first population-based incidence Erlotinib price study of HCC in Australia, we have shown that the incidence of HCC in Melbourne RAD001 manufacturer is higher than previously reported in Victoria. This has important implications for the allocation of healthcare resources. Hepatitis C and alcohol are the leading causes of HCC. Tumours diagnosed within surveillance programs had earlier stage disease, suggesting that increased uptake of surveillance may improve clinical outcomes. X ZHOU,1 K SHAW,1 L ALGIE,2 J FAWCETT,2 K STUART1 1Department of Gastroenterology and Hepatology Princess Alexandra Hospital, Brisbane, Australia, 2Liver Transplant Services, Princess Alexandra Hospital, Brisbane, Australia

Background: The Barcelona Clinic Liver Cancer (BCLC) staging system is the most widely used treatment algorithm for Hepatocellular Carcinoma (HCC). Patient performance status (PS) is a key component of the revised BCLC criteria. Patients with an ECOG status of ≥1 are categorised as BCLC Stage C irrespective of tumour size and number. Other HCC staging systems place more emphasis on the characteristics of the tumour than the health status of the patient in their treatment decision making process. Aims and methods: The aim of this study was to assess the influence of PS on treatment selection and overall survival in patients with BCLC Early Stage HCC. A retrospective review was conducted of all patients with 上海皓元医药股份有限公司 BCLC Early HCC who were treated with curative intent using radiofrequency ablation (RFA), surgical resection (SR) or liver transplantation (LT) at a single Australian liver transplant centre between January 2005 and June 2012. Early HCC was defined as a single tumour ≤6.5 cm or ≤3 tumours, none greater than 4.5 cm in maximum diameter with a total tumour diameter of ≤8 cm. Patients were divided into two groups based on their PS (ECOG 0–1; good performance group, ECOG ≥2 poor performance group). Demographic data, clinical and laboratory characteristics, treatment selection and overall survival were compared between the two groups.

RESULTS: HCV infected patients exhibited significantly higher antiCD81/CLDN1 antibody titers compared to healthy individuals (p < 0.0001). Among HCV infected patients, individuals who Selisistat cleared the virus had higher antibody titers during the acute phase of infection compared to individuals progressing to chronic infection (p = 0.0197). Furthermore, in the majority of patients that resolved hepatitis C, virus-neutralizing antibody titers were associated with anti-CD81/CLDN1 titers. CoNCLUSION: Our data suggest that anti-receptor

autoantibodies are produced in the early phase of viral infection and that these antibodies could contribute to spontaneous viral clearance in conjunction with anti-viral responses. Characterization of these anti-receptor autoantibodies may open new avenues to prevent and treat HCV infection. Disclosures: Michael Roggendorf – Speaking and Teaching: Abbott, novartis Thomas Berg – Advisory Committees or Review

Panels: Gilead, BMS, Roche, Tibotec, Vertex, Jannsen, Novartis, Abbott, Merck; Consulting: Gilead, BMS, Roche, Tibotec; Vertex, Janssen; Grant/Research Support: Gilead, BMS, Roche, īibotec; Vertex, Jannssen, Schering Plough, Boehringer ingelheim, Novartis; Speaking and Teaching: Gilead, BMS, Roche, īibotec; Vertex, Janssen, Schering Plough, Novartis, Merck, Bayer The following people have nothing to disclose: Rajeevkumar G. Tawar, Helga Meisel, Mirjam B. Zeisel, Thomas F. Baumert BACKGROUND & AIMS: MicroRNAs (miRNAs) are an important class of small non-coding RNA molecules that bind to PF-01367338 cell line their complementary sequence on their target mRNAs, resulting in translational repression. MiRNAs play important roles in development, metabolism, infection, and cancer. In this study, we analyzed the changes of miRNA expression associated with the progression of chronic hepatitis C (CHC). METHODS: Liver biopsy samples were obtained from 54 patients with CHC

and patients with a normal liver. All CHC patients were infected with genotype 1b HCV. MiRNAs were obtained from the biopsy specimens, and the expression of 328 miRNAs was determined with the ĪaqMan Real-time PCR detection system using the ĪaqMan MicroRNA Assays Human Panel. The functional relevance of fibrosis-related miRNAs 上海皓元 was evaluated in Lx- cells, a human stellate cell line, by the overexpression or knocking down of specific miRNAs using mimic-miRNA or antimiRNA. HCV replication was evaluated in Huh-7.5 cells using the infectious genotype 1a clone pH77S.3/Gluc2A with a Gaussia reporter gene. HCV translation (HCV-IRES) activity was monitored in the stably transformed IRES reporter cell line RCF26.. RESULTS: The expression of 55 miRNAs was significantly different between patients with early stage fibrosis (F1-2) and advanced stage fibrosis (F3-4), and the prediction performance was 83% accurate according to the support vector machine algorithm.

RESULTS: HCV infected patients exhibited significantly higher antiCD81/CLDN1 antibody titers compared to healthy individuals (p < 0.0001). Among HCV infected patients, individuals who selleck compound cleared the virus had higher antibody titers during the acute phase of infection compared to individuals progressing to chronic infection (p = 0.0197). Furthermore, in the majority of patients that resolved hepatitis C, virus-neutralizing antibody titers were associated with anti-CD81/CLDN1 titers. CoNCLUSION: Our data suggest that anti-receptor

autoantibodies are produced in the early phase of viral infection and that these antibodies could contribute to spontaneous viral clearance in conjunction with anti-viral responses. Characterization of these anti-receptor autoantibodies may open new avenues to prevent and treat HCV infection. Disclosures: Michael Roggendorf – Speaking and Teaching: Abbott, novartis Thomas Berg – Advisory Committees or Review

Panels: Gilead, BMS, Roche, Tibotec, Vertex, Jannsen, Novartis, Abbott, Merck; Consulting: Gilead, BMS, Roche, Tibotec; Vertex, Janssen; Grant/Research Support: Gilead, BMS, Roche, īibotec; Vertex, Jannssen, Schering Plough, Boehringer ingelheim, Novartis; Speaking and Teaching: Gilead, BMS, Roche, īibotec; Vertex, Janssen, Schering Plough, Novartis, Merck, Bayer The following people have nothing to disclose: Rajeevkumar G. Tawar, Helga Meisel, Mirjam B. Zeisel, Thomas F. Baumert BACKGROUND & AIMS: MicroRNAs (miRNAs) are an important class of small non-coding RNA molecules that bind to check details their complementary sequence on their target mRNAs, resulting in translational repression. MiRNAs play important roles in development, metabolism, infection, and cancer. In this study, we analyzed the changes of miRNA expression associated with the progression of chronic hepatitis C (CHC). METHODS: Liver biopsy samples were obtained from 54 patients with CHC

and patients with a normal liver. All CHC patients were infected with genotype 1b HCV. MiRNAs were obtained from the biopsy specimens, and the expression of 328 miRNAs was determined with the ĪaqMan Real-time PCR detection system using the ĪaqMan MicroRNA Assays Human Panel. The functional relevance of fibrosis-related miRNAs MCE was evaluated in Lx- cells, a human stellate cell line, by the overexpression or knocking down of specific miRNAs using mimic-miRNA or antimiRNA. HCV replication was evaluated in Huh-7.5 cells using the infectious genotype 1a clone pH77S.3/Gluc2A with a Gaussia reporter gene. HCV translation (HCV-IRES) activity was monitored in the stably transformed IRES reporter cell line RCF26.. RESULTS: The expression of 55 miRNAs was significantly different between patients with early stage fibrosis (F1-2) and advanced stage fibrosis (F3-4), and the prediction performance was 83% accurate according to the support vector machine algorithm.

The Asian Pacific Society for Biomedical Research on Alcoholism may select a young scientist for this award every second year, which allows him to travel to the ESBRA congress, and ESBRA will

also select one young scientist from Europe, which would strengthen the bonds between our societies. I am sure that Hiro would have liked this idea. Ladies and gentlemen, I want to thank you for this invitation today, which gave me the opportunity to tribute a great man, a great scientist, and a great friend. We all miss him; I miss him, but we will keep him in our hearts. Thank you very much. “
“Liver granulomas are focal accumulations of chronic inflammatory cells, including macrophages, easily demarcated selleck from the surrounding tissue, which develop as a reaction to foreign agents. There are multiple causes of hepatic granulomas, the most frequent being primary biliary cirrhosis, sarcoidosis and tuberculosis. The clinical manifestations, treatment, and prognosis are those of the underlying etiology, although in some cases liver granulomas per AZD3965 clinical trial se can lead to hepatomegaly and elevations in alkaline phosphatase. The differential diagnosis can be made histologically by searching for the etiologic agent within the granuloma and/or by analyzing the location and morphological characteristics of the granuloma. The clinical history, including a drug history,

is of the essence in establishing the cause for liver granulomas. “
“Fat-specific protein 27 (Fsp27) is a lipid droplet-associated protein that promotes lipid droplet (LD) growth and triglyceride (TG) storage in white adipocytes. Fsp27 is also

highly expressed in the steatotic liver and contributes to TG accumulation. In this study, we discovered that the liver produces Fsp27β, an alternative Fsp27 isoform, which contains 10 additional amino acids at the N-terminus of the original Fsp27 (Fsp27α). White adipose tissue (WAT) and the liver specifically expressed Fsp27α and Fsp27β transcripts, respectively, which were driven by distinct promoters. The Fsp27β promoter was activated by the liver-enriched transcription factor cyclic-AMP-responsive-element-binding protein H (CREBH) but not by peroxisome proliferator-activated receptor gamma (PPARγ) which activated the Fsp27α promoter. Enforced expression of the constitutively active CREBH strongly MCE公司 induced Fsp27β and the human ortholog CIDEC2 in mouse hepatocytes and HepG2 cells, respectively. In contrast, loss of CREBH decreased hepatic Fsp27β in fasted mice, suggesting that CREBH plays a critical role in Fsp27β expression in the liver. Similar to Fsp27α, Fsp27β localized on the surface of lipid droplets and suppressed lipolysis. Consequently, enforced expression of Fsp27β or CREBH promoted lipid droplet enlargement and TG accumulation in the liver. Our study demonstrated that the CREBH-Fsp27β axis is important for regulating lipid droplet dynamics and TG storage in the liver.

The results of the base case analysis for the three competing strategies showing total costs, benefits (LYS) and cost per QALY gained are shown in Table 4. Lifestyle modification as a baseline strategy cost $46,000 for the cohort with a total average benefit of 6.2 LYS. Pioglitazone in addition to lifestyle modification was more costly than lifestyle modification alone, but delivered greater health benefits and was cost-effective,

with an incremental benefit of an additional 4.7 LYS and an ICER of $2748/QALY gained. Vitamin E in addition to lifestyle modification was also cost-effective, with additional benefit of 0.6 LYS, resulting in an ICER of $8475/QALY gained. A direct comparison of the two pharmacological strategies indicated that pioglitazone was more cost-effective, with an ICER of $2056/QALY gained

compared with vitamin E. The results of a one-way sensitivity analysis that tested find more for influential variables in the pioglitazone strategy are shown in Fig. 2. The vertical line represents the ICER for the base case estimate. The arrows show the direction of movement of the ICER across the range that the variable was tested. There were four key variables (represented as horizontal bars) that had a meaningful effect on the ICER. For example, if the annual probability of death in decompensated NASH was 15%, the ICER was more than $7000/QALY gained; however, if the probability was 38%, the ICER was less than $1000, indicating pioglitazone was more cost-effective when the risk of death in decompensated disease increased. selleck chemical Similarly, as the benefit of pioglitazone in preventing progression to cirrhosis increased, the cost-benefit ratio improved. A one-way sensitivity analysis testing variables in the vitamin E strategy indicated that the ability of vitamin E

to prevent decompensation, and the probability of death due to decompensated disease, were the most influential variables. Nevertheless, the ICER remained cost-effective across the ranges tested for these probabilities, likely reflecting the cheap cost of vitamin E. The model was tested over a discounting rate that varied from 3%-8%. At the highest rate of discounting (8%), the ICER for both strategies became more cost-effective (ICERs of $945/QALY 上海皓元医药股份有限公司 gained for pioglitazone and $5475/QALY gained for vitamin E). Two-way sensitivity analyses were performed to assess the change in the ICER when two variables were varied simultaneously, in order to find thresholds at which the drugs were no longer cost-effective. Two-way sensitivity analyses in the pioglitazone strategy indicated that if the likelihood of developing cirrhosis for people with advanced fibrosis was less than 2% per year, then lifestyle modification was the more cost-effective option. At probabilities equal or greater than 2%, pioglitazone was more cost-effective.

Results: In 4 cases of abdominal mass, there was 1 castleman disease,1 maligant mesenchymal tumorin,1 schwannoma and 1 epithelioid mesotheliomas. The ultrasonoscopy and result of pathology and BI6727 cytology were showed in figure A(a), B(b), C(c) and D(d) Conclusion: Ultrasonographically guided puncture could make a definitive diagnose for abdominal mass and provides important value for clinical treatment. Key Word(s): 1. ultrasound-guided; 2. abdominal mass;

3. biopsy; Presenting Author: QIAN ZHANG Additional Authors: CHUNYU ZHANG, YONGGUI ZHANG, WENQIAN QI Corresponding Author: QIAN ZHANG Affiliations: China-Japan Union hospital of JiLin University Objective: PME/PDE ratio of 31p MRS was correlated better with the fibrosis score. This study was to investigate the utility of

31P MR spectroscopy as a noninvasive http://www.selleckchem.com/products/gdc-0068.html test to access the liver histology after pegylated interferon α-2a in chronic HBV patients. Methods: Patients initially received conventional Peg-IFNα-2a 180 μg (sc) once weekly for 48 weeks. Every patients was examined with 31p MRS (3.0T PHILIPS) when before antiviral therapy,24 weeks and 48weeks. Patients were divided into SVR group and no SVR group (sustained virologic response, SVR). Compare the 31p MRS PME/PDE of the same group patients at different therapy weeks, and the one of different group patients at the same therapy weeks. Results: Whenever the SVR group and no SVR group, PME/PDE ratio of 31p MRS at 48 weeks was significant lower than the one at24weeks, and the two were lower than the one before antiviral therapy. When 24weeks and 48weeks, PME/PDE ratio of 31p MRS in SVR group was significant lower than no SVR group, but this was not been seen when before antiviral therapy. Conclusion: The 31p MRS PME/PDE ratio decreased in chronic HBV patients during pegylated interferon α-2a antiviral therapy. 31p MRS PME/PDE ratio can be used as biomarkers in a noninvasive test of liver histology response to treatment. Key Word(s): 1. 31p MRS; 2. liver histology; 3. peg-IFN α-2a; 4. chronic HBV; Presenting Author: QIAN ZHANG Additional Authors: WENQIAN QI, CHUANYU ZHANG,

YONGGUI MCE ZHANG Corresponding Author: QIAN ZHANG, YONGGUI ZHANG Affiliations: China-Japan Union hospital of JiLin University Objective: PME/PDE ratio of 31p MRS was correlated better with the fibrosis score. This study was to investigate the correlations between 31P MRS and histological grading and staging in chronic HBV patients. Methods: 20 chronic HBV patients and 10 healthy volunteers was includes this study. 20 chronic HBV patients was examined with liver biopsy and 31p MRS, 10 healthy volunteers was examined with 31p MRS. In 31P MRS, peak area of PME, PDE, PCr, Pi, γ-ATP, β-ATP, α-ATP were calculated. Biospy specimens were socred for fibrosis and necroinflammation according to the Knodell histology index (HAI). Results: There were differences in PME%, PDE% and PME/PDE between chronic HBV and control group.